Degarelix – Uses, Dosage, Side Effects, Interaction Degarelix is a parenterally administered, gonadotropin-releasing hormone (GnRH) antagonist that effectively blocks androgen production and is used to treat advanced prostate cancer. Degarelix therapy is associated with serum enzyme elevations during therapy but has yet to be linked to instances of clinically apparent acute liver injury. Testosterone is a male hormone that promotes the growth of many prostate tumors and therefore reducing circulating testosterone to very low (castration) levels is often the treatment goal in the management of advanced prostate cancer. Degarelix has an immediate onset of action, binding to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocking their interaction with GnRH. This induces a fast and profound reduction in luteinizing hormone (LH), follicle-stimulating hormone (FSH), and in turn, testosterone suppression.[rx] Degarelix is a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing the secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes. Degarelix Acetate is the acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing the secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes. Mechanism of Action Degarelix competitively inhibits GnRH receptors in the pituitary gland, preventing the release of luteinizing hormone (LH) and follicle-stimulating hormone. Reduced LH suppresses testosterone release, which slows growth and reduces the size of prostate cancers. Degarelix is a selective gonadotrophin-releasing-hormone (GnRH) antagonist that competitively and reversibly binds to the pituitary GnRH receptors, thereby rapidly reducing the release of the gonadotrophins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), and thereby reducing the secretion of testosterone (T) by the testes. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that removes the source of androgen. Unlike GnRH agonists, GnRH antagonists do not induce an LH surge with subsequent testosterone surge/tumor stimulation and potential symptomatic flare after the initiation of treatment or Degarelix, a synthetic decapeptide, is a gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, gonadorelin) antagonist. The drug immediately, competitively, and reversibly binds to and blocks GnRH receptors in the pituitary, thereby reducing the release of gonadotropins (i.e., luteinizing hormone [LH], follicle-stimulating hormone [FSH]) and, consequently, testosterone without initial stimulation of the hypothalamic-pituitary-gonadal axis and the associated testosterone surge. Degarelix appears to have low histamine-releasing potential compared with other GnRH antagonists; there have been no signs of immediate- or late-onset systemic allergic reactions with degarelix. Degarelix is a synthetic derivative of GnRH decapeptide, the ligand of the GnRH receptor. Gonadotropin and androgen production result from the binding of endogenous GnRH to the GnRH receptor. Degarelix antagonizes the GnRH receptor which in turn blocks the release of LH and FSH from the pituitary. LF and FSH decrease in a concentration-dependent manner. The reduction in LH leads to a decrease in testosterone release from the testes. Gonadotrophin-releasing hormone receptors, GnRH1 and GnRH2 receptors (provisional nomenclature, also called Type I and Type II GnRH receptor, respectively ) have been cloned from numerous species, most of which express two or three types of GnRH receptor. GnRH I (p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) is a hypothalamic decapeptide also known as luteinizing hormone-releasing hormone, gonadoliberin, luliberin, gonadorelin or simply as GnRH. It is a member of a family of similar peptides found in many species including GnRH II (pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2 (which is also known as chicken GnRH-II). Receptors for three forms of GnRH exist in some species but only GnRH I and GnRH II and their cognate receptors have been found in mammals. GnRH1 receptors are expressed by pituitary gonadotrophs, where they mediate the effects of GnRH on gonadotropin hormone synthesis and secretion that underpin central control of mammalian reproduction. GnRH analogs are used in assisted reproduction and to treat steroid hormone-dependent conditions. Notably, agonists cause desensitization of GnRH-stimulated gonadotropin secretion, and the consequent reduction in circulating sex steroids is exploited to treat hormone-dependent cancers of the breast, ovary, and prostate. GnRH1 receptors are selectively activated by GnRH I and all lack the COOH-terminal tails found in other GPCRs. GnRH2 receptors do have COOH-terminal tails and (where tested) are selective for GnRH II over GnRH I. GnRH2 receptors are expressed by some primates but not by humans. Phylogenetic classifications divide GnRH receptors into three or five groups and highlight examples of gene loss through evolution, with humans retaining only one ancient gene. The structure of the GnRH1 receptor in complex with elagolix has been elucidated. Indications Degarelix is used for the management of advanced prostate cancer. FIRMAGON is a gonadotrophin-releasing hormone (GnRH) antagonist indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer for treatment of high-risk localized and locally advanced hormone-dependent prostate cancer in combination with radiotherapy as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localized or locally advanced hormone dependent prostate cancer. Degarelix is a parenterally administered, gonadotropin-releasing hormone (GnRH) antagonist that effectively blocks androgen production and is used to treat advanced prostate cancer. Intended to treat patients with advanced prostate cancer … slows the growth and progression of prostate cancer by suppressing testosterone Use in Cancer Degarelix is approved to treat: Prostate cancer is advanced. Contraindications low amount of magnesium in the blood low amount of potassium in the blood prolonged QT interval on EKG chronic heart failure abnormal EKG with QT changes from birth liver problems decreased calcification or density of bone pregnancy Dosage Strengths: 80 mg; 120 mg Prostate Cancer Initial Dose: 240 mg administered as 2 subcutaneous injections of 120 mg each at a concentration of 40 mg/mL. Maintenance Dose: 80 mg administered as 1 subcutaneous injection at a concentration of 20 mg/mL every 28 days. Administer the first maintenance dose 28 days after the initial dose. Renal Dose Adjustments Mild Renal Impairment (CrCl 50 to 80 mL/min): No adjustment recommended. Moderate to Severe Renal Impairment (CrCl less than 50 mL/min): Use with caution. Liver Dose Adjustments Mild to Moderate Hepatic Impairment (Child-Pugh A and B): No adjustment recommended. Severe Hepatic Impairment (Child-Pugh C): Data not available; use with caution. Administration Advice: Administer this drug in the abdominal region only. Vary the injection site periodically to minimize patient discomfort, and administer in abdomen areas not exposed to pressure (e.g., not close to the waistband or belt, not close to the ribs). Perform a slow, deep subcutaneous injection over 30 seconds. This drug is for subcutaneous injection only; do not administer intravenously or intramuscularly. Use this drug only as a first-line androgen deprivation therapy; there is no data available on the use of this drug in patients who have failed treatment with GnRH agonists (e.g., leuprorelin, goserelin). Confirm serum testosterone levels are remaining sufficiently suppressed if a patient’s clinical response appears to be sub-optimal. Side Effects The Most Common pain, redness, swelling, hardness, or itching in the place where the medication was injected hot flashes excessive sweating or night sweats nausea constipation diarrhea weight gain or loss weakness dizziness headache tiredness difficulty falling asleep or staying asleep enlargement of the breasts decreased sexual desire or ability back or joint pain hives rash difficulty breathing or swallowing rapid, irregular, or pounding heartbeat swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs hoarseness fluttering feeling in the chest fainting painful, frequent, or difficult urination fever or chills More common Back pain blurred vision dizziness fever flushing or redness of the skin hard lump headache nervousness pain pounding in the ears slow or fast heartbeat small lumps under the skin swelling unusually warm skin fast or pounding heartbeats, fluttering in your chest; shortness of breath; sudden dizziness (like you might pass out); or severe headache, blurred vision, and pounding in your neck or ears. hot flashes; abnormal liver function tests; or pain, swelling, redness, itching, or a hard lump where the medicine was injected. weight gain; Rare Bladder pain bloody or cloudy urine chills decrease in testicle size decreased interest in sexual intercourse difficult, burning, or painful urination difficulty in moving frequent urge to urinate inability to have or keep an erection increased sweating loss in sexual ability, desire, drive, or performance lower back or side pain muscle pain or stiffness pain in the joints Chest pain or discomfort fainting irregular heartbeat pounding heartbeat Cough difficulty swallowing hives, itching, or skin rash puffiness or swelling of the eyelids or around the eyes, face, lips or tongue tightness in the chest trouble breathing unusual tiredness or weakness Drug Interaction Acrivastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Acrivastine. Adenosine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Adenosine. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Degarelix. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Degarelix. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Degarelix. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Degarelix. Amifampridine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Amifampridine. Amiodarone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Degarelix. Amitriptyline The risk or severity of QTc prolongation can be increased when Degarelix is combined with Amitriptyline. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Degarelix. Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Degarelix. Anagrelide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Anagrelide. Antazoline The risk or severity of QTc prolongation can be increased when Degarelix is combined with Antazoline. Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Degarelix. Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Degarelix. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Degarelix. Aripiprazole lauroxil The risk or severity of QTc prolongation can be increased when Degarelix is combined with Aripiprazole lauroxil. Arsenic trioxide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Arsenic trioxide. Artemether The risk or severity of QTc prolongation can be increased when Degarelix is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Articaine. Asenapine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Asenapine. Astemizole The risk or severity of QTc prolongation can be increased when Degarelix is combined with Astemizole. Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Degarelix. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Degarelix. Atropine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Atropine. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Degarelix. Azithromycin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Azithromycin. Bedaquiline The risk or severity of QTc prolongation can be increased when Degarelix is combined with Bedaquiline. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Degarelix. Benzocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Benzyl alcohol. Bepridil The risk or severity of QTc prolongation can be increased when Degarelix is combined with Bepridil. Berotralstat The risk or severity of QTc prolongation can be increased when Degarelix is combined with Berotralstat. Bilastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Bilastine. Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Degarelix. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Degarelix. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Degarelix. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Degarelix. Bupivacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Bupivacaine. Buserelin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Buserelin. Butacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Degarelix is combined with Butriptyline. Capsaicin The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Capsaicin. Carbinoxamine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Carbinoxamine. Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Degarelix. Ceritinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ceritinib. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Degarelix. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Chlorcyclizine. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Chloroprocaine. Chloroquine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Chloroquine. Chlorpheniramine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Chlorpheniramine. Chlorpromazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Chlorpromazine. Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Degarelix. Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Degarelix. Cinchocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Cinchocaine. Cinnarizine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Cinnarizine. Cinoxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Cinoxacin. Ciprofloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ciprofloxacin. Cisapride The risk or severity of QTc prolongation can be increased when Degarelix is combined with Cisapride. Citalopram The risk or severity of QTc prolongation can be increased when Degarelix is combined with Citalopram. Clarithromycin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Clemastine. Clofazimine The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Degarelix. Clomipramine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Clomipramine. Clozapine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Clozapine. Cocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Cocaine. Crizotinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Crizotinib. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Degarelix. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Degarelix. Dabrafenib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dabrafenib. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Degarelix. Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Degarelix. Delafloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Delafloxacin. Delamanid Degarelix may increase the QTc-prolonging activities of Delamanid. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Degarelix. Desipramine The risk or severity of QTc prolongation can be increased when Desipramine is combined with Degarelix. Desloratadine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Desloratadine. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Deutetrabenazine. Dexbromphenirami The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Degarelix. Dexchlorphenirami The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dexchlorpheniramine maleate. Digitoxin The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Degarelix. Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Degarelix. Diltiazem The risk or severity of QTc prolongation can be increased when Degarelix is combined with Diltiazem. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dimenhydrinate. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Diphenhydramine. Disopyramide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Disopyramide. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Degarelix. Dofetilide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dofetilide. Dolasetron The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dolasetron. Domperidone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Domperidone. Dosulepin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dosulepin. Doxepin The risk or severity of QTc prolongation can be increased when Doxepin is combined with Degarelix. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Degarelix. Dronedarone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Droperidol. Dyclonine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Dyclonine. Ebastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ebastine. Efavirenz The risk or severity of QTc prolongation can be increased when Degarelix is combined with Efavirenz. You Might Also Read Uses Indications of Memantine Hydrochloride Tablets Eliglustat The risk or severity of QTc prolongation can be increased when Degarelix is combined with Eliglustat. Emedastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Emedastine. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Degarelix. Encorafenib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Encorafenib. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Degarelix. Entrectinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Entrectinib. Epinastine The risk or severity of QTc prolongation can be increased when Epinastine is combined with Degarelix. Eribulin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Eribulin. Erlotinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Erlotinib. Erythromycin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Degarelix. Escitalopram The risk or severity of QTc prolongation can be increased when Degarelix is combined with Escitalopram. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Degarelix. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Degarelix. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Etidocaine. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Degarelix. Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Degarelix. Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Degarelix. Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Degarelix. Fexinidazole The risk or severity of adverse effects can be increased when Degarelix is combined with Fexinidazole. Flecainide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Flecainide. Fluconazole The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Degarelix. Fluorouracil The risk or severity of QTc prolongation can be increased when Degarelix is combined with Fluorouracil. Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Degarelix. Flupentixol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Flupentixol. Fluspirilene The risk or severity of QTc prolongation can be increased when Degarelix is combined with Fluspirilene. Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Degarelix. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Degarelix. Fostemsavir The risk or severity of QTc prolongation can be increased when Degarelix is combined with Fostemsavir. Gadobenic acid The risk or severity of QTc prolongation can be increased when Degarelix is combined with Gadobenic acid. Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Degarelix. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Degarelix. Gemifloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Gemifloxacin. Gilteritinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Gilteritinib. Glasdegib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Glasdegib. Goserelin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Goserelin. Granisetron The risk or severity of QTc prolongation can be increased when Degarelix is combined with Granisetron. Grepafloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Grepafloxacin. Halofantrine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Halofantrine. Haloperidol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Haloperidol. Histrelin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Histrelin. Hydrochlorothia The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Degarelix. Hydroxychloroq The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Degarelix. Hydroxyzine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Degarelix. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Degarelix. Ibutilide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ibutilide. Iloperidone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Iloperidone. Imatinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Imatinib. Imipramine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Imipramine. Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Degarelix. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Degarelix. Inotersen The risk or severity of QTc prolongation can be increased when Degarelix is combined with Inotersen. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Degarelix. Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Degarelix. Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Degarelix. Ivabradine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ivabradine. Ivosidenib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ivosidenib. Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Degarelix. Lacidipine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lacidipine. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Degarelix. Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Degarelix. Lefamulin Lefamulin may increase the QTc-prolonging activities of Degarelix. Lenvatinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lenvatinib. Leuprolide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Leuprolide. Levacetylmethadol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Levacetylmethadol. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Degarelix. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Degarelix. Levofloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Levofloxacin. Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Degarelix. Levosimendan The risk or severity of QTc prolongation can be increased when Degarelix is combined with Levosimendan. Lidocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lidoflazine. Lofexidine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lofexidine. Lomefloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lomefloxacin. Loperamide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Loperamide. Lopinavir The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Degarelix. Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Degarelix. Lumefantrine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lumefantrine. Lurasidone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lurasidone. Macimorelin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Macimorelin. Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Degarelix. Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Degarelix. Meloxicam The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Mepivacaine. Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Degarelix. Mesoridazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mesoridazine. Methadone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Methadone. Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Degarelix. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Degarelix. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Degarelix. Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Degarelix. Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Degarelix. Mifepristone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mifepristone. Mirabegron The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mirabegron. Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Degarelix. Mizolastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mizolastine. Mobocertinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mobocertinib. You Might Also Read Ifosfamide - Uses, Dosage, Side Effects, Interaction Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Degarelix. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Degarelix. Moxifloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Moxifloxacin. Nalidixic acid The risk or severity of QTc prolongation can be increased when Degarelix is combined with Nalidixic acid. Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Degarelix. Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Degarelix. Nifedipine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Nifedipine. Nilotinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Nilotinib. Nilvadipine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Nilvadipine. Nimodipine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Nimodipine. Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Degarelix. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Degarelix. Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Degarelix. Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Degarelix. Ofloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ofloxacin. Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Degarelix. Olodaterol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Olodaterol. Ondansetron The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ondansetron. Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Degarelix. Oxaliplatin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Oxaliplatin. Oxatomide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Oxatomide. Oxetacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Oxybuprocaine. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Degarelix. Pacritinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Pacritinib. Paliperidone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Paliperidone. Panobinostat The risk or severity of QTc prolongation can be increased when Degarelix is combined with Panobinostat. Papaverine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Papaverine. Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Degarelix. Pazopanib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Pazopanib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Degarelix. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Degarelix. Pentamidine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Pentamidine. Perflutren The risk or severity of QTc prolongation can be increased when Degarelix is combined with Perflutren. Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Degarelix. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Degarelix. Phenol The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Phenol. Pimozide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Pimozide. Pinaverium The risk or severity of QTc prolongation can be increased when Degarelix is combined with Pinaverium. Pitolisant Degarelix may increase the QTc-prolonging activities of Pitolisant. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Degarelix. Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Degarelix. Pramocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Pramocaine. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Degarelix. Prenylamine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Prenylamine. Prilocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Prilocaine. Primaquine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Primaquine. Probucol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Probucol. Procainamide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Procainamide. Procaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Procaine. Prochlorperazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Prochlorperazine. Promazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Promazine. Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Degarelix. Propafenone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Proparacaine. Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Degarelix. Propoxycaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Propoxycaine. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Degarelix. Quetiapine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Quetiapine. Quinidine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Quinidine. Quinine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Quinine. Ranolazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ranolazine. Relugolix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Relugolix. Ribociclib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ribociclib. Rilpivirine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Rilpivirine. Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Degarelix. Ritonavir The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Degarelix. Romidepsin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Romidepsin. Ropivacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Ropivacaine. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Degarelix. Roxithromycin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Roxithromycin. Rupatadine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Rupatadine. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Degarelix. Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Degarelix. Saquinavir The risk or severity of QTc prolongation can be increased when Degarelix is combined with Saquinavir. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Degarelix. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Degarelix. Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Degarelix. Sotalol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sotalol. Sparfloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sparfloxacin. Sulfamethoxazole The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Degarelix. Sulfisoxazole The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sulfisoxazole. Sulpiride The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sulpiride. Sultopride The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sultopride. Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Degarelix. Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Degarelix. Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Degarelix. Telavancin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Telavancin. Telithromycin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Telithromycin. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Degarelix. Terfenadine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Terfenadine. Terlipressin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Terlipressin. Tetrabenazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Tetrabenazine. Tetracaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Tetracaine. Thioridazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Thioridazine. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Degarelix. Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Degarelix. Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Degarelix. Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Degarelix. Toremifene The risk or severity of QTc prolongation can be increased when Degarelix is combined with Toremifene. You Might Also Read Tacrolimus Anhydrous - Uses, Dosage, Side Effects Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Degarelix. Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Degarelix. Triclabendazole The risk or severity of QTc prolongation can be increased when Degarelix is combined with Triclabendazole. Trimebutine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Trimebutine. Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Degarelix. Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Degarelix. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Degarelix. Triptorelin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Triptorelin. Trovafloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Trovafloxacin. Valproic acid The risk or severity of QTc prolongation can be increased when Degarelix is combined with Valproic acid. Vandetanib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Vandetanib. Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Degarelix. Vemurafenib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Vemurafenib. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Degarelix. Vilanterol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Vilanterol. Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Degarelix. Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Degarelix. Ziprasidone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ziprasidone. Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Degarelix. Zuclopenthixol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Zuclopenthixol. Pregnancy and Lactation FDA Pregnancy Risk Category: X AU TGA pregnancy category D Pregnancy There are no controlled data on human pregnancy. Drugs that have caused, are suspected to have caused, or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in the use of the drug in pregnant women clearly outweigh the potential benefits. Lactation There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. How should this medicine be used? Degarelix injection comes as a powder to be mixed with liquid and injected under the skin in the stomach area, away from the ribs and waistline. It is usually injected once every 28 days by a doctor or nurse in a medical facility. After you receive a dose of degarelix injection, be sure that your belt or waistband does not put pressure on the place where the medication was injected. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. Other uses for this medicine This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before receiving degarelix injection, tell your doctor and pharmacist if you are allergic to degarelix injection, any other medications, or any of the ingredients in degarelix injection. Ask your pharmacist or check the patient’s information for a list of the ingredients. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Cordarone), disopyramide (Norpace), quinidine, procainamide, or sotalol (Betapace). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have or have ever had long QT syndrome (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death); high or low levels of calcium, potassium, magnesium, or sodium in your blood; or heart, liver, or kidney disease. women who are or who may become pregnant should not receive degarelix injections. Degarelix injection may harm the fetus. If you receive degarelix injection while you are pregnant, call your doctor immediately. If you are breastfeeding, talk to your doctor before you receive degarelix injection. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022201lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022201s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022201.pdf https://www.cancer.gov/about-cancer/treatment/drugs/degarelix https://pubchem.ncbi.nlm.nih.gov/compound/Degarelix https://pubchem.ncbi.nlm.nih.gov/compound/Degarelix-acetate-hydrate https://www.drugs.com/degarelix.html https://go.drugbank.com/drugs/DB06699 https://en.wikipedia.org/wiki/Degarelix https://medlineplus.gov/druginfo/meds/a609022.html https://www.webmd.com/drugs/2/drug-151919/degarelix-subcutaneous/details/list-contraindications https://www.mayoclinic.org/drugs-supplements/degarelix-subcutaneous-route/side-effects/drg-20072529? ChEBI Degarelix http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:135961 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology DrugBank https://www.drugbank.ca/legal/terms_of_use Degarelix https://www.drugbank.ca/drugs/DB06699 FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking DEGARELIX https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Degarelix https://www.ncbi.nlm.nih.gov/books/n/livertox/Degarelix/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48385 NCI Thesaurus Tree https://ncit.nci.nih.gov ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Degarelix [USAN:INN:BAN] https://chem.nlm.nih.gov/chemidplus/sid/0214766786 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Degarelix https://comptox.epa.gov/dashboard/DTXSID801026401 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice 214766-78-6 https://echa.europa.eu/information-on-chemicals 214766-78-6 https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/243915 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking DEGARELIX https://gsrs.ncats.nih.gov/ginas/app/beta/substances/SX0XJI3A11 Hazardous Substances Data Bank (HSDB) Degarelix https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7817 ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html DEGARELIX ACETATE https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=FIRMAGON Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads DEGARELIX https://www.dgidb.org/drugs/DEGARELIX IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license degarelix https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5585 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Degarelix http://idrblab.net/ttd/data/drug/details/D0Y7KH Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking degarelix https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Firmagon (EMEA/H/C/000986) https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking DEGARELIX https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Degarelix https://www.cancer.gov/about-cancer/treatment/drugs/degarelix NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html degarelix https://rxnav.nlm.nih.gov/id/rxnorm/475230 PubChem https://pubchem.ncbi.nlm.nih.gov Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=117082048-132220312 Wikidata https://creativecommons.org/publicdomain/zero/1.0/ Degarelix https://www.wikidata.org/wiki/Q1182795 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html https://www.ncbi.nlm.nih.gov/mesh/67431566 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html KEGG https://www.kegg.jp/kegg/legal.html Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets NORMAN Suspect List Exchange https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ PATENTSCOPE (WIPO) SID 404043624 https://pubchem.ncbi.nlm.nih.gov/substance/404043624 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More